Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies

Its prognostic value on short-term recurrences

Piero Gaglia, Amelia Bernardi, Tiziana Venesio, Beatrice Caldarola, Danilo Lauro, Alberto P M Cappa, Paolo Calderini, Daniel S. Liscia

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The prognostic value of breast cancer proliferative activity was evaluated in 385 women operated for primary, non-metastasised mammary carcinoma. Cell kinetics was measured using two immunohistochemical techniques. Cells in S-phase of cell cycle were labelled in vitro by incubation of fresh tissue fragments with 5-bromo 2-deoxyuridine (BrdU), a thymidine analogue. Nuclei of cells in active DNA synthesis were stained by an anti-BrdU monoclonal antibody (Mab). Cells in interphase and mitosis were detected with Ki-67, a Mab that is known to react with a nuclear antigen present in G1/S/G2/M phases of cell cycle, but not in resting cells. This reagent provides a means of evaluating the growth fraction of neoplastic cells. BrdU was incorporated in a proportion of tumour cells ranging from 0.1 to 65.5% (median 6.8%). In the panel of tumours presented in this report the median percentage of Ki-67 positive cells (Ki-67 score) was 9.0% (range 0.1-77%). The relationship between disease-free survival (DFS), BrdU labelling index, Ki-67 score and 13 different clinico-pathological variables was investigated by multivariate analysis, using the Cox proportional hazards model. Axillary node status (P = 0.009) and Ki-67 score (P = 0.038) emerged as independent prognostic factors. Nodal status and tumour growth fraction allowed division of patients into groups at different risk of relapse: tumours with a proliferative index below the median value showed a lower recurrence rate than tumours with a high proliferative activity (P <0.001). In particular, no relapse occurred in pN0 patients bearing carcinomas with a Ki-67 labelling <9.0% 4 years after surgery. These findings suggest that the evaluation of proliferative activity in breast cancer enhances the probability of correctly predicting outcome after surgery and could be of assistance in the planning of adjuvant therapies.

Original languageEnglish
Pages (from-to)1509-1513
Number of pages5
JournalEuropean Journal of Cancer
Volume29
Issue number11
DOIs
Publication statusPublished - 1993

Fingerprint

Deoxyuridine
Cell Proliferation
Breast Neoplasms
Recurrence
Antibodies
Neoplasms
Cell Cycle
Monoclonal Antibodies
Nuclear Antigens
G2 Phase
Interphase
Bromodeoxyuridine
Growth
Cell Nucleus
S Phase
Proportional Hazards Models
Mitosis
Cell Division
Thymidine
Disease-Free Survival

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies : Its prognostic value on short-term recurrences. / Gaglia, Piero; Bernardi, Amelia; Venesio, Tiziana; Caldarola, Beatrice; Lauro, Danilo; Cappa, Alberto P M; Calderini, Paolo; Liscia, Daniel S.

In: European Journal of Cancer, Vol. 29, No. 11, 1993, p. 1509-1513.

Research output: Contribution to journalArticle

Gaglia, Piero ; Bernardi, Amelia ; Venesio, Tiziana ; Caldarola, Beatrice ; Lauro, Danilo ; Cappa, Alberto P M ; Calderini, Paolo ; Liscia, Daniel S. / Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies : Its prognostic value on short-term recurrences. In: European Journal of Cancer. 1993 ; Vol. 29, No. 11. pp. 1509-1513.
@article{0fc89de2a6de430cb0428754d3a06846,
title = "Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: Its prognostic value on short-term recurrences",
abstract = "The prognostic value of breast cancer proliferative activity was evaluated in 385 women operated for primary, non-metastasised mammary carcinoma. Cell kinetics was measured using two immunohistochemical techniques. Cells in S-phase of cell cycle were labelled in vitro by incubation of fresh tissue fragments with 5-bromo 2-deoxyuridine (BrdU), a thymidine analogue. Nuclei of cells in active DNA synthesis were stained by an anti-BrdU monoclonal antibody (Mab). Cells in interphase and mitosis were detected with Ki-67, a Mab that is known to react with a nuclear antigen present in G1/S/G2/M phases of cell cycle, but not in resting cells. This reagent provides a means of evaluating the growth fraction of neoplastic cells. BrdU was incorporated in a proportion of tumour cells ranging from 0.1 to 65.5{\%} (median 6.8{\%}). In the panel of tumours presented in this report the median percentage of Ki-67 positive cells (Ki-67 score) was 9.0{\%} (range 0.1-77{\%}). The relationship between disease-free survival (DFS), BrdU labelling index, Ki-67 score and 13 different clinico-pathological variables was investigated by multivariate analysis, using the Cox proportional hazards model. Axillary node status (P = 0.009) and Ki-67 score (P = 0.038) emerged as independent prognostic factors. Nodal status and tumour growth fraction allowed division of patients into groups at different risk of relapse: tumours with a proliferative index below the median value showed a lower recurrence rate than tumours with a high proliferative activity (P <0.001). In particular, no relapse occurred in pN0 patients bearing carcinomas with a Ki-67 labelling <9.0{\%} 4 years after surgery. These findings suggest that the evaluation of proliferative activity in breast cancer enhances the probability of correctly predicting outcome after surgery and could be of assistance in the planning of adjuvant therapies.",
author = "Piero Gaglia and Amelia Bernardi and Tiziana Venesio and Beatrice Caldarola and Danilo Lauro and Cappa, {Alberto P M} and Paolo Calderini and Liscia, {Daniel S.}",
year = "1993",
doi = "10.1016/0959-8049(93)90284-M",
language = "English",
volume = "29",
pages = "1509--1513",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "11",

}

TY - JOUR

T1 - Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies

T2 - Its prognostic value on short-term recurrences

AU - Gaglia, Piero

AU - Bernardi, Amelia

AU - Venesio, Tiziana

AU - Caldarola, Beatrice

AU - Lauro, Danilo

AU - Cappa, Alberto P M

AU - Calderini, Paolo

AU - Liscia, Daniel S.

PY - 1993

Y1 - 1993

N2 - The prognostic value of breast cancer proliferative activity was evaluated in 385 women operated for primary, non-metastasised mammary carcinoma. Cell kinetics was measured using two immunohistochemical techniques. Cells in S-phase of cell cycle were labelled in vitro by incubation of fresh tissue fragments with 5-bromo 2-deoxyuridine (BrdU), a thymidine analogue. Nuclei of cells in active DNA synthesis were stained by an anti-BrdU monoclonal antibody (Mab). Cells in interphase and mitosis were detected with Ki-67, a Mab that is known to react with a nuclear antigen present in G1/S/G2/M phases of cell cycle, but not in resting cells. This reagent provides a means of evaluating the growth fraction of neoplastic cells. BrdU was incorporated in a proportion of tumour cells ranging from 0.1 to 65.5% (median 6.8%). In the panel of tumours presented in this report the median percentage of Ki-67 positive cells (Ki-67 score) was 9.0% (range 0.1-77%). The relationship between disease-free survival (DFS), BrdU labelling index, Ki-67 score and 13 different clinico-pathological variables was investigated by multivariate analysis, using the Cox proportional hazards model. Axillary node status (P = 0.009) and Ki-67 score (P = 0.038) emerged as independent prognostic factors. Nodal status and tumour growth fraction allowed division of patients into groups at different risk of relapse: tumours with a proliferative index below the median value showed a lower recurrence rate than tumours with a high proliferative activity (P <0.001). In particular, no relapse occurred in pN0 patients bearing carcinomas with a Ki-67 labelling <9.0% 4 years after surgery. These findings suggest that the evaluation of proliferative activity in breast cancer enhances the probability of correctly predicting outcome after surgery and could be of assistance in the planning of adjuvant therapies.

AB - The prognostic value of breast cancer proliferative activity was evaluated in 385 women operated for primary, non-metastasised mammary carcinoma. Cell kinetics was measured using two immunohistochemical techniques. Cells in S-phase of cell cycle were labelled in vitro by incubation of fresh tissue fragments with 5-bromo 2-deoxyuridine (BrdU), a thymidine analogue. Nuclei of cells in active DNA synthesis were stained by an anti-BrdU monoclonal antibody (Mab). Cells in interphase and mitosis were detected with Ki-67, a Mab that is known to react with a nuclear antigen present in G1/S/G2/M phases of cell cycle, but not in resting cells. This reagent provides a means of evaluating the growth fraction of neoplastic cells. BrdU was incorporated in a proportion of tumour cells ranging from 0.1 to 65.5% (median 6.8%). In the panel of tumours presented in this report the median percentage of Ki-67 positive cells (Ki-67 score) was 9.0% (range 0.1-77%). The relationship between disease-free survival (DFS), BrdU labelling index, Ki-67 score and 13 different clinico-pathological variables was investigated by multivariate analysis, using the Cox proportional hazards model. Axillary node status (P = 0.009) and Ki-67 score (P = 0.038) emerged as independent prognostic factors. Nodal status and tumour growth fraction allowed division of patients into groups at different risk of relapse: tumours with a proliferative index below the median value showed a lower recurrence rate than tumours with a high proliferative activity (P <0.001). In particular, no relapse occurred in pN0 patients bearing carcinomas with a Ki-67 labelling <9.0% 4 years after surgery. These findings suggest that the evaluation of proliferative activity in breast cancer enhances the probability of correctly predicting outcome after surgery and could be of assistance in the planning of adjuvant therapies.

UR - http://www.scopus.com/inward/record.url?scp=0027202516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027202516&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(93)90284-M

DO - 10.1016/0959-8049(93)90284-M

M3 - Article

VL - 29

SP - 1509

EP - 1513

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -